- Details
- Description
Packaging Size:
30T/Bottle
Strength:
25mg
Composition:
Lorlatinnib
Treatment:
ALK positive metastatic NSCLC
Form:
Tablet
Brand:
LORLADX
Quantity Unit:
25mg*30T/bottle
Manufacturer:
BIGBEAR Pharma,Laos PDR
Lorlatinib is used to treat a certain type of non-small cell lung cancer (NSCLC) in adults that has spread to other parts of the body. Lorlatinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply.
Non-small Cell Lung Cancer
Indicated for metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test 100 mg PO qDay with or without food Continue until disease progression or unacceptable toxicityDosage Modifications
Dosage modifications for adverse reactions
- First dose reduction: 75 mg qDay
- Second dose reduction: 50 mg qDay
- Unable to tolerate 50 mg qDay: Permanently discontinue
